warming up, page-8

Different business model as far as I know, GBI are doing HPV as their initial product which has been already been validated by the scientific community and then pioneered by Digene and now Hologic...clinical data and established re-imbersement is already there, PLT never had the data or the support of the scientific community or the insurance companies.

HTX appears to have the same issues as PLT but at a market cap of < $5m with HTX I was prepared to take the punt a few months ago...PLT had a market cap of $100m+ not too long back, so did FER for that matter...never stacked up IMO.